Bellicum Pharmaceuticals Leases Space for Pilot Manufacturing Facility
“Bringing manufacturing in-house allows us to build upon our process and
assay development expertise and streamline the production of our cell
therapy product candidates, under our full control,” said
About
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company is using its proprietary Chemical Induction of Dimerization, or CID, technology platform to engineer and control components of the immune system in real time. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation, or HSCT, CAR T cell therapy, and dendritic cell vaccines.
Forward-Looking Statement
This press release contains forward-looking statements for purposes
of the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Bellicum may, in some cases, use terms such as
"predicts," "believes," "potential," "proposed," "continue,"
"estimates," "anticipates," "expects," "plans," "intends," "may,"
"could," "might," "will," "should" or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things: the
timing of our clinical trials and of our research and development
activities relating to BPX-501 and our expectations regarding our other
programs. Various factors may cause differences between Bellicum’s
expectations and actual results as discussed in greater detail in
Bellicum’s filings with the
Source:
Investors
Bellicum Pharmaceuticals
Alan Musso,
832-384-1116
CFO
amusso@bellicum.com
or
Media
BMC
Communications
Brad Miles, 646-513-3125
bmiles@bmccommunications.com